The primary owner of Ozempic maker Novo Nordisk A/S is launching a network of research incubators across Europe, seeking to create breakthrough obesity and diabetes treatments by turning academic discoveries into commercial ventures.
The CardioMetabolic Bridge program will open its first location in London this month, followed by sites in Italy and Germany later this year, according to a statement from the Novo Nordisk Foundation, which holds a controlling stake in the Danish drugmaker.